Castle Biosciences Inc CSTL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Late-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management
-
New Study Shows That TissueCypher® Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's Esophagus
-
New Study Highlights Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of AdvanceAD-Tx™
-
Castle Biosciences to Open New Laboratory Facility in Scottsdale
-
New Decision Modeling Study Demonstrates TissueCypher® Significantly Improves Risk-Aligned Management for Patients with Barrett's Esophagus
-
JAAD Publication Shows Improved Performance of DecisionDx®-SCC
-
Castle Biosciences to Participate in Upcoming Investor Conferences
-
Castle Biosciences Approved for Dual Listing on Nasdaq Texas
Trading Information
- Previous Close Price
- $35.26
- Day Range
- $34.75–35.92
- 52-Week Range
- $17.72–44.28
- Bid/Ask
- $22.00 / $40.00
- Shares Outstanding
- 30.55M
- Market Cap
- $1.09B
- Volume/Avg
- 167,719 / 390,304
Key Statistics
- Price/Earnings (Normalized)
- 87.35
- Price/Sales
- 2.95
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Core
- Total Number of Employees
- 1,002
Valuation
|
Metric
|
CSTL
|
|---|---|
Price/Earnings (Normalized) | 87.35 |
Price/Book Value | 2.31 |
Price/Sales | 2.95 |
Price/Cash Flow | 29.82 |
Price/Earnings
CSTL
Financial Strength
|
Metric
|
CSTL
|
|---|---|
Quick Ratio | 5.58 |
Current Ratio | 6.04 |
Interest Coverage | −78.55 |
Quick Ratio
CSTL
Profitability
|
Metric
|
CSTL
|
|---|---|
Return on Assets (Normalized) | 2.87% |
Return on Equity (Normalized) | 3.45% |
Return on Invested Capital (Normalized) | 1.58% |
Return on Assets
CSTL
Diagnostics & Research Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| LOCK|$Crx?&WF | LOCK|L@ | $242B | |||
| Danaher Corp
DHR
| LOCK|Bws<kx?w | LOCK|&r | $150B | |||
| Agilent Technologies Inc
A
| LOCK|wY$ns<w | LOCK|pb& | $47B | |||
| IQVIA Holdings Inc
IQV
| LOCK|K&?Clkd | LOCK|j@^N | $43B | |||
| Waters Corp
WAT
| LOCK|V#f>Ps | LOCK|z^ | $42B | |||
| Illumina Inc
ILMN
| LOCK|FsLd<@B | LOCK|Tq&Mp | $41B | |||
| IDEXX Laboratories Inc
IDXX
| LOCK|WJjD<q&% | LOCK|&d! | $41B | |||
| Mettler-Toledo International Inc
MTD
| LOCK|@%f@jp?x | LOCK|$^f%C | $30B | |||
| Quest Diagnostics Inc
DGX
| LOCK|%%G!<X< | LOCK|%<!@! | $26B | |||
| Labcorp Holdings Inc
LH
| LOCK|^!VT$nV | LOCK|b>Vg< | $25B |
United States